Abstract 929P
Background
The incidence of Laryngeal Squamous Cell Carcinoma (LSCC) has increased over the past 30 years, presenting new challenges in the management of this disease. In response to these evolving needs, we developed a machine learning (ML) prognostic model to optimize the treatment strategies for patients diagnosed with advanced LSCC.
Methods
Data from 2000 to 2020 were obtained from the SEER database. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test was used to compare variables. The Kaplan-Meier estimator, log-rank test, and Cox regression analysis identified prognostic factors for overall survival (OS) and cancer-specific survival (CSS). We constructed prognostic models using ML algorithms to predict 5-year survival. The data were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
A total of 7,350 patients were included: 2,689 with glottic (GC), 4,349 with supraglottic (SuGC), and 312 with subglottic (SG) cancers. The median patient age was 60 years. A total of 88.8% of the patients had a T3 and T4. The largest racial group was white, comprising 74.8% of the cases, and 21.1% of the cases were black. Most cases were stage IV AJCC (89.5%), and 41.4% of the patients had N2. Of the patients, 52% underwent total laryngectomy, which was the most common surgical procedure (39.1%). ML was used to identify the most important features of GC, including age, sex, and AJCC staging. Age and sex were considered as key factors for SuGC metastasis. For SC, the most important features identified were surgery combined with radiotherapy, sex, and surgery combined with chemoradiotherapy.
Conclusions
This study presents ML models tailored to three anatomical sites of LSCC. Key factors such as age and sex for GC and SuGC and treatment combinations for SG. These models underscore their utility in personalized medicine, enabling clinicians to customize treatment strategies based on individual characteristics and improve clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1036P - Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance
Presenter: Yumo Xie
Session: Poster session 03
1037P - Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Presenter: Hakimeh Ebrahimi-Nik
Session: Poster session 03
Resources:
Abstract
1038P - Interactions of immune checkpoint blockade and regulatory T cells
Presenter: Dylan Muldoon
Session: Poster session 03
1039P - Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy
Presenter: Eduard Teixidor Vilà
Session: Poster session 03
1040P - Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study
Presenter: Changjing Cai
Session: Poster session 03
Resources:
Abstract
1041P - ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1
Presenter: Pierre MARSCHALL
Session: Poster session 03
1042P - Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform
Presenter: Raffaella Ergasti
Session: Poster session 03
1043P - Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
Presenter: Kirsty Crame
Session: Poster session 03
1044P - UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region
Presenter: Kirsty Crame
Session: Poster session 03
1045P - The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors
Presenter: Yongchang Zhang
Session: Poster session 03